Media headlines about Nantkwest (NASDAQ:NK) have trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nantkwest earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.2524436757157 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
NK has been the topic of several analyst reports. BidaskClub cut Nantkwest from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 10th. ValuEngine upgraded Nantkwest from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $4.00.
NK traded up $0.08 during midday trading on Friday, reaching $3.06. The company had a trading volume of 186,200 shares, compared to its average volume of 226,038. The company has a quick ratio of 6.54, a current ratio of 6.54 and a debt-to-equity ratio of 0.01. The stock has a market cap of $234.26 million, a price-to-earnings ratio of -2.55 and a beta of 2.79. Nantkwest has a 1 year low of $2.66 and a 1 year high of $8.45.
In other Nantkwest news, Director Steve Gorlin sold 26,835 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $4.13, for a total transaction of $110,828.55. Following the sale, the director now directly owns 246,280 shares in the company, valued at $1,017,136.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 237,368 shares of company stock valued at $925,876. Corporate insiders own 72.30% of the company’s stock.
NantKwest, Inc, a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.